Stock Traders Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the recipient of unusually large options trading on Tuesday. Stock traders bought 6,387 call options on the company. This is an increase of 60% compared to the typical daily volume of 3,991 call options.

Esperion Therapeutics Trading Up 9.0 %

ESPR stock traded up $0.19 during trading on Tuesday, reaching $2.31. The stock had a trading volume of 30,105,989 shares, compared to its average volume of 6,781,332. The stock’s 50 day moving average is $2.33 and its two-hundred day moving average is $2.06. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The firm has a market cap of $437.51 million, a PE ratio of -1.09 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business earned ($0.76) EPS. On average, research analysts anticipate that Esperion Therapeutics will post -0.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ESPR shares. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.33.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in ESPR. SG Americas Securities LLC bought a new stake in shares of Esperion Therapeutics in the 1st quarter worth about $69,000. Boomfish Wealth Group LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $80,000. Mesirow Financial Investment Management Inc. bought a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $54,000. Summit Financial LLC lifted its stake in shares of Esperion Therapeutics by 66.8% during the 1st quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 10,355 shares during the last quarter. Finally, Simplicity Wealth LLC bought a new position in Esperion Therapeutics in the 1st quarter valued at $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.